HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00292409

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

Medication studyAges 18–65
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateMarch 2005
Recruitment status
Completed
Enrollment listed in the registry
400
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Not clearly listed
Age range
From 18 Years to 65 Years
Official registry ID
NCT00292409
Official title
Show the full official title

A Prospective Open-Label Study of Aripiprazole in the Management of Patients With Schizophrenia in General Psychiatric Practices

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me